den Elzen Wendy P J, Lefèbre-van de Fliert Anne A, Virgini Vanessa, Mooijaart Simon P, Frey Peter, Kearney Patricia M, Kerse Ngaire, Mallen Christian D, McCarthy Vera J C, Muth Christiane, Rosemann Thomas, Russell Audrey, Schers Henk, Stott David J, de Waal Margot W M, Warner Alex, Westendorp Rudi G J, Rodondi Nicolas, Gussekloo Jacobijn
Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.
Department of General Internal Medicine, Inselspital, University of Bern, Bern, Switzerland.
Br J Gen Pract. 2015 Feb;65(631):e121-32. doi: 10.3399/bjgp15X683569.
There is limited evidence about the impact of treatment for subclinical hypothyroidism, especially among older people.
To investigate the variation in GP treatment strategies for older patients with subclinical hypothyroidism depending on country and patient characteristics.
Case-based survey of GPs in the Netherlands, Germany, England, Ireland, Switzerland, and New Zealand.
The treatment strategy of GPs (treatment yes/no, starting-dose thyroxine) was assessed for eight cases presenting a woman with subclinical hypothyroidism. The cases differed in the patient characteristics of age (70 versus 85 years), vitality status (vital versus vulnerable), and thyroid-stimulating hormone (TSH) concentration (6 versus 15 mU/L).
A total of 526 GPs participated (the Netherlands n = 129, Germany n = 61, England n = 22, Ireland n = 21, Switzerland n = 262, New Zealand n = 31; overall response 19%). Across countries, differences in treatment strategy were observed. GPs from the Netherlands (mean treatment percentage 34%), England (40%), and New Zealand (39%) were less inclined to start treatment than GPs in Germany (73%), Ireland (62%), and Switzerland (52%) (P = 0.05). Overall, GPs were less inclined to start treatment in 85-year-old than in 70-year-old females (pooled odds ratio [OR] 0.74 [95% confidence interval [CI] = 0.63 to 0.87]). Females with a TSH of 15 mU/L were more likely to get treated than those with a TSH of 6 mU/L (pooled OR 9.49 [95% CI = 5.81 to 15.5]).
GP treatment strategies of older people with subclinical hypothyroidism vary largely by country and patient characteristics. This variation underlines the need for a new generation of international guidelines based on the outcomes of randomised clinical trials set within primary care.
关于亚临床甲状腺功能减退症治疗效果的证据有限,尤其是在老年人中。
调查不同国家和患者特征的老年亚临床甲状腺功能减退症患者的全科医生治疗策略差异。
对荷兰、德国、英国、爱尔兰、瑞士和新西兰的全科医生进行基于病例的调查。
评估全科医生对8例亚临床甲状腺功能减退症女性患者的治疗策略(是否治疗、起始剂量甲状腺素)。这些病例在年龄(70岁与85岁)、健康状况(健康与脆弱)和促甲状腺激素(TSH)浓度(6与15 mU/L)等患者特征方面存在差异。
共有526名全科医生参与(荷兰129名,德国61名,英国22名,爱尔兰21名,瑞士262名,新西兰31名;总体回复率19%)。不同国家之间观察到治疗策略存在差异。荷兰(平均治疗百分比34%)、英国(40%)和新西兰(39%)的全科医生比德国(73%)、爱尔兰(62%)和瑞士(52%)的全科医生更不愿意开始治疗(P = 0.05)。总体而言,全科医生对85岁女性开始治疗的意愿低于70岁女性(合并比值比[OR] 0.74 [95%置信区间[CI] = 0.63至0.87])。TSH为15 mU/L的女性比TSH为6 mU/L的女性更有可能接受治疗(合并OR 9.49 [95% CI = 5.81至15.5])。
老年亚临床甲状腺功能减退症患者的全科医生治疗策略因国家和患者特征而异。这种差异凸显了基于初级保健中随机临床试验结果制定新一代国际指南的必要性。